Roche's first-half sales hit by poor exchange rate and further Tamiflu decline
This article was originally published in Scrip
Executive Summary
Roche's pharmaceutical sales for the first half of this year were down by 6% to CHF17.3 billion ($17 billion) when compared with the same period last year, but increased by 3% in local currencies. Roche Pharmaceuticals' sales were down by 4% at CHF11 billion andChugai, of which Roche owns 59.9%, had sales of CHF1.5 billion, down by 13%.